GET DAILY SIGNALSICU Medical (ICUI) Delivers Q4 2025 Earnings Beat Despite Revenue Decline from Divestiture
Key Takeaways
- ICU Medical reported fourth-quarter 2025 revenue of $540.7 million, down roughly 14% year over year, reflecting the May 2025 divestiture of its IV Solutions business into a joint venture.
- Adjusted diluted earnings per share (EPS) came in at $1.91, above the consensus estimate of about $1.71, while adjusted EBITDA was $98.2 million.
- Organic revenue grew 2% in the quarter and 5% for the full year, led by record results in the Consumables and Infusion Systems segments.
- For fiscal 2026, management guided to adjusted EPS of $7.75 to $8.45 and adjusted EBITDA of $400 million to $430 million.
- Tariffs remained a headwind, reducing adjusted EBITDA by roughly $25 million for the year, with a similar drag expected to persist into 2026.
Putting the Earnings in Context
ICU Medical’s fourth-quarter results wrap up a pivotal year for the infusion-therapy and critical-care device maker. The company spent 2025 integrating the Smiths Medical acquisition while completing the disposition of its IV Solutions business into the Otsuka-ICU Medical joint venture, a move that reshaped its reported revenue profile. Those structural changes make year-over-year comparisons less meaningful on a headline basis, so I focus on organic growth and margin progress instead. With adjusted gross margin holding above 40% and adjusted EBITDA recovering from integration-related pressure, the report offers a key checkpoint on whether management’s multi-year turnaround is translating into durable, higher-quality earnings as the company pivots toward growth in its core consumables and infusion systems franchises. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Numbers
For the quarter ended December 31, 2025, ICUI posted total revenue of $540.7 million, compared with $629.8 million a year earlier. The decline primarily reflects the deconsolidation of the IV Solutions business, which was contributed to the Otsuka-ICU Medical joint venture effective May 1, 2025. On an organic basis, revenue rose 2%, and full-year organic growth reached 5%.
GAAP net loss narrowed to $15.7 million, or $0.64 per diluted share, from a loss of $23.8 million, or $0.97 per share, in the prior-year quarter. Adjusted diluted EPS was $1.91, down from $2.11 a year ago but above the roughly $1.71 consensus estimate. Adjusted EBITDA declined to $98.2 million from $105.5 million, pressured by the IV Solutions deconsolidation and about $11 million of tariff expense in the quarter.
By product line, Consumables revenue rose to $284.7 million and Infusion Systems grew to $176.3 million, while Vital Care declined to $79.7 million, reflecting the IV Solutions divestiture. For fiscal 2026, the company guided to GAAP EPS of $1.03 to $1.74, adjusted EPS of $7.75 to $8.45, and adjusted EBITDA of $400 million to $430 million.
How the Market Responded
ICU Medical’s results were broadly in line with its own expectations, and the adjusted EPS beat relative to consensus provided a modest positive signal. However, sentiment heading into the print was already tempered by the structural revenue decline from the IV Solutions divestiture and the ongoing tariff burden. The company’s closing of the U.S. Food and Drug Administration (FDA) warning letter tied to its legacy Smiths Medical operations was a notable operational milestone, easing a regulatory overhang. At the same time, the 2026 adjusted EBITDA guidance of $400 million to $430 million remains below the company’s earlier longer-term targets, which has kept investors focused on execution rather than rewarding the quarter outright.
Looking Ahead to 2026 and Key Factors to Monitor
Looking ahead, management’s 2026 guidance implies low- to mid-single-digit organic revenue growth, adjusted gross margin of roughly 41%, and a continued emphasis on free cash flow generation and debt reduction. Tariffs are expected to pressure gross margin by approximately 2% of revenue during the year, an issue management is addressing through supply-chain and manufacturing changes that may take time to fully materialize.
Investors should watch whether the Consumables and Infusion Systems segments sustain their momentum, given management’s confidence in mid-single-digit growth. The Smiths Medical integration remains a central theme, with completed site consolidations expected to unlock further synergies. Capital-market activity around the company’s pump portfolio, including the Duo and Solo platforms in the U.S. and the international product lineup, will also be an important demand signal.
Finally, balance-sheet progress matters. With net debt just below $1 billion and a target of roughly 2x net leverage by early 2027, disciplined cash deployment and any commentary on returning capital to shareholders could shape sentiment in the quarters ahead.
Tools That Help Me Stay on Top of the Data
When I want to dig deeper into earnings trends or compare ICUI against peers, I turn to Tickeron’s AI Screener. It lets me quickly filter stocks by fundamentals, technical patterns, and AI-driven signals so I can focus on what matters most for the names I follow. The tool has become a regular part of my workflow because it surfaces ideas and context faster than manual searches alone.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ICUI in downward trend: price may drop because broke its higher Bollinger Band on November 04, 2026
ICUI broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 47 similar instances where the stock broke above the upper band. In 34 of the 47 cases the stock fell afterwards. This puts the odds of success at 72%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 59 cases where ICUI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 68%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICUI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on ICUI as a result. In 65 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for ICUI just turned positive on November 04, 2026. Looking at past instances where ICUI's MACD turned positive, the stock continued to rise in 28 of 52 cases over the following month. The odds of a continued upward trend are 54%.
ICUI moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ICUI crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +3.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICUI advanced for three days, in 189 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The Aroon Indicator entered an Uptrend today. In 139 of 204 cases where ICUI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. ICUI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.006) is normal, around the industry mean (5.069). ICUI has a moderately high P/E Ratio (143.850) as compared to the industry average of (40.009). Projected Growth (PEG Ratio) (0.081) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.808) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICUI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of medical technologies
Industry PharmaceuticalsOther
Advertisement